This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Apolipoprotein genotyping in Alzheimer's disease

Authoring team

A consensus document published in 1996 provides guidance on the use of apolipoprotein E genotyping in Alzheimer's disease. The main points of the report were (1):

  • apoE genotyping is not recommended for risk assessment in individuals without symptoms or signs of Alzheimer's disease
  • apoE-4 is more common in patients with Alzheimer's disease than in either the normal population or those patients with non-Alzheimer's dementia; for these reasons some physicians may wish to use apoE genotyping as an adjunct in the diagnosis of Alzheimer's disease
  • apoE genotyping should not be used as the sole diagnostic test in Alzheimer's disease
  • the social and financial implications of apoE genotyping should be considered before investigating a patient.

Reference:

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.